Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Sage Therapeutics to Present at Upcoming March Investor Conferences
-
SAGE Therapeutics (SAGE) Enters Sales Agreement with Cowen for Up to $250M Shares
-
Sage Therapeutics to Present at Upcoming September Investor Conferences
-
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
-
Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
-
Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
-
Sage Therapeutics (SAGE) PT Raised to $105 at Cowen Following WATERFALL Data
-
Sage Therapeutics to Present at Upcoming Investor Conferences
-
Cowen Bullish on Sage Therapeutics (SAGE) as 2021 is Expected to be a 'Transformative' Year
-
Sage Therapeutics (SAGE) PT Raised to $100 at Cowen
-
Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
-
Sage Therapeutics (SAGE) PT Lowered to $96 at Cowen, Following Pharma Stdufy Fail
-
SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen
-
Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference
-
SAGE Therapeutics (SAGE) Prices 3.5M Shares at $164
-
Sage Therapeutics Prices Public Offering of Common Stock
-
Sage Therapeutics (SAGE) PT Raised to $202 at Cowen
-
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
-
SAGE Therapeutics (SAGE) Prices 3.53M Share Common Offering at $85/Sh
-
Sage Therapeutics Prices Public Offering of Common Stock
-
Sage Therapeutics (SAGE) PT Raised to $135 at Cowen
-
Sage Therapeutics (SAGE) PT Lowered to $90 at Cowen
-
Cowen Starts Sage Therapeutics (SAGE ) at Outperform, Top SMIDcap Pick
-
SAGE Therapeutics (SAGE) Prices 4.4M Common Stock Offering at $39.75/Share
-
Sage Therapeutics Announces Pricing of Public Offering of Common Stock
-
Pre-Open Stock Movers 09/08: (RPRX) (RAD) (JUNO) Higher; (GEVO) (NLST) (TSCO) (PIR) Lower (more...)
-
Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Pre-Open Stock Movers 03/30: (ACAD) (VICL) (ANTM) Higher; (CTRV) (VRNT) (LNDC) Lower (more...)
-
Sage Therapeutics to Present at the Cowen & Co. 36th Annual Health Care Conference
-
SAGE Therapeutics (SAGE) Prices 3.16M Shares at $47.50/Share
-
Sage Therapeutics Announces Pricing of Public Offering of Common Stock
-
SAGE Therapeutics (SAGE) Announces $150M Common Stock Offering
-
Sage Therapeutics Announces Proposed Public Offering of Common Stock
-
Sage Therapeutics (SAGE) SAGE-547 Results Seen as 'Promising', Price Target Raised to $108 at Cowen
-
Cowen Starts Sage Therapeutics (SAGE) at Outperform
-
SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
-
SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
-
SAGE Therapeutics (SAGE) Prices ~2.3M Common Share Offering at $52.50/Share
-
SAGE Therapeutics Announces Pricing of Public Offering of Common Stock
-
SAGE Therapeutics (SAGE) Announces $100M Common Stock Offering
-
SAGE Therapeutics Announces Proposed Public Offering of Common Stock
-
SAGE Therapeutics Announces Proposed Public Offering of Common Stock

